share_log

Prime Medicine (NYSEARCA:PRME) Shares Up 7.4%

Prime Medicine (NYSEARCA:PRME) Shares Up 7.4%

Prime Medicine（纽约证券交易所代码：PRME）股价上涨7.4％
Financial News Live ·  2022/12/01 23:21

Prime Medicine, Inc. (NYSEARCA:PRME – Get Rating)'s stock price shot up 7.4% during trading on Tuesday . The stock traded as high as $18.79 and last traded at $18.73. 7,198 shares changed hands during mid-day trading, a decline of 97% from the average session volume of 235,939 shares. The stock had previously closed at $17.44.

Prime Medicine, Inc.（纽约证券交易所代码：PRME — 获取评级）的股价在周二的交易中飙升了7.4％。该股交易价格高达18.79美元，最后交易价格为18.73美元。在午盘交易中，有7,198股易手，较235,939股的平均交易量下降了97％。该股此前收于17.44美元。

Analyst Ratings Changes

分析师评级变化

Several research firms have commented on PRME. The Goldman Sachs Group began coverage on shares of Prime Medicine in a research note on Monday, November 14th. They issued a "neutral" rating and a $22.00 price target for the company. Jefferies Financial Group began coverage on shares of Prime Medicine in a research report on Monday, November 14th. They set a "buy" rating and a $25.00 price objective for the company. JPMorgan Chase & Co. began coverage on shares of Prime Medicine in a research report on Monday, November 14th. They set an "overweight" rating and a $27.00 price objective for the company. Finally, Morgan Stanley began coverage on shares of Prime Medicine in a research report on Monday, November 14th. They set an "equal weight" rating and a $23.00 price objective for the company.

几家研究公司对PRME发表了评论。高盛集团于11月14日星期一在一份研究报告中开始报道Prime Medicine的股票。他们为该公司发布了 “中性” 评级和22.00美元的目标股价。杰富瑞金融集团在11月14日星期一的一份研究报告中开始报道Prime Medicine的股票。他们为公司设定了 “买入” 评级和25.00美元的目标股价。摩根大通于11月14日星期一在一份研究报告中开始报道Prime Medicine的股票。他们为公司设定了 “增持” 评级和27.00美元的目标股价。最后，摩根士丹利在11月14日星期一的一份研究报告中开始报道Prime Medicine的股票。他们为公司设定了 “同等权重” 的评级和23.00美元的目标价格。

Get
得到
Prime Medicine
优质医学
alerts:
警报：

Prime Medicine Stock Down 0.8 %

优质药品股票下跌0.8％

The business's fifty day moving average price is $19.27 and its 200 day moving average price is $19.89.

该公司的五十天移动平均价格为19.27美元，其200天移动平均价格为19.89美元。

Insider Transactions at Prime Medicine

Prime Medicine 的内部交易

In related news, Director Thomas Cahill bought 400,000 shares of the stock in a transaction on Monday, October 24th. The shares were bought at an average cost of $17.00 per share, for a total transaction of $6,800,000.00. Following the completion of the transaction, the director now owns 5,305,679 shares of the company's stock, valued at approximately $90,196,543. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through
在相关新闻方面，董事托马斯·卡希尔在10月24日星期一的一笔交易中购买了40万股股票。这些股票的平均购买成本为每股17.00美元，总交易额为6,800,000.00美元。交易完成后，该董事现在拥有公司5,305,679股股票，价值约90,196,543美元。此次收购已在向美国证券交易委员会提交的一份文件中披露，该文件可通过以下方式获取
this link
这个链接
. In related news, Director Thomas Cahill bought 400,000 shares of the stock in a transaction on Monday, October 24th. The shares were bought at an average cost of $17.00 per share, for a total transaction of $6,800,000.00. Following the completion of the transaction, the director now owns 5,305,679 shares of the company's stock, valued at approximately $90,196,543. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through
。在相关新闻方面，董事托马斯·卡希尔在10月24日星期一的一笔交易中购买了40万股股票。这些股票的平均购买成本为每股17.00美元，总交易额为6,800,000.00美元。交易完成后，该董事现在拥有公司5,305,679股股票，价值约90,196,543美元。此次收购已在向美国证券交易委员会提交的一份文件中披露，该文件可通过以下方式获取
this link
这个链接
. Also, major shareholder 2019 Gp L.L.C. Gv bought 800,000 shares of the stock in a transaction on Monday, October 24th. The shares were bought at an average price of $17.00 per share, for a total transaction of $13,600,000.00. Following the completion of the transaction, the insider now directly owns 11,522,248 shares of the company's stock, valued at approximately $195,878,216. The disclosure for this purchase can be found
。此外，主要股东2019年Gp L.L.C. Gv于10月24日星期一通过交易购买了80万股股票。这些股票的平均价格为每股17.00美元，总交易额为13,600,000.00美元。交易完成后，知情人现在直接拥有该公司11,522,248股股票，价值约195,878,216美元。可以找到此次收购的披露信息
here
这里
.
。

Prime Medicine Company Profile

普瑞美药公司简介

(Get Rating)

（获取评级）

Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.

Prime Medicine, Inc是一家生物技术公司，通过部署基因编辑技术提供基因疗法来治疗疾病。它为 Prime Editor 提供 Prime Editor 蛋白，包括 Cas 蛋白和逆转录酶之间的融合；以及一个 pegRNA，它将 Prime Editor 靶向特定的基因组位置，为对目标 DNA 序列进行所需编辑提供了模板。

Featured Stories

精选故事

  • Get a free copy of the StockNews.com research report on Prime Medicine (PRME)
  • Will Easing Of Covid Rules Slash Risk For Chinese EV Maker NIO?
  • Santa Claus Rally? Here's What Needs to Happen
  • Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
  • Dark Clouds Are Gathering For Cloud Stocks
  • 3 Dividend Growers With Good 2023 Growth Prospects
  • 免费获取 StockNews.com 关于 Prime Medicine (PRME) 的研究报告
  • 放宽Covid规则会降低中国电动汽车制造商蔚来的风险吗？
  • 圣诞老人拉力赛？这是需要发生的事情
  • Cosmos Holdings 可能是具有短期风险的长期买入
  • 乌云密布云密布股票
  • 3 个 2023 年增长前景良好的股息增长者

Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.

接收Prime Medicine Daily的新闻和评级——在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收Prime Medicine及相关公司的最新新闻和分析师评级的简明每日摘要。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发